Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11/18/24 21:06 | 11/18/24 | AURA | Health | BioPrd | Biological Products, (No Diag | Hopkins Janet Jill | MA | O | Chief Me | 1 | S | -111 | 9.36 | 0 | -12 | 152 | D | |||||||||||||||
10/29/24 20:28 | 10/29/24 | AURA | Health | BioPrd | Biological Products, (No Diag | De Los Pinos Elisabet | MA | DO | See Rema | 4 | S.d | -500 | 7.73 | 0 | -65 | 461 | D | |||||||||||||||
10/29/24 20:23 | 10/29/24 | AURA | Health | BioPrd | Biological Products, (No Diag | Elazzouzi Amy | MA | O | VP,Finan | 1 | S | -6 | 10.74 | 0 | -1 | 39 | D | |||||||||||||||
10/21/24 18:23 | 10/18/24 | AURA | Health | BioPrd | Biological Products, (No Diag | Feder Julie B | MA | O | CFO | 2 | M.d | 389 | 7.74 | 0 | 50 | 60 | 134 | D | ||||||||||||||
10/21/24 18:23 | 10/18/24 | AURA | Health | BioPrd | Biological Products, (No Diag | Feder Julie B | MA | O | CFO | 2 | S.d | -389 | 7.74 | 0 | -50 | 134 | D | |||||||||||||||
10/16/24 21:25 | 10/16/24 | AURA | Health | BioPrd | Biological Products, (No Diag | Plavsic Mark | MA | O | CTO | 1 | S | -73 | 9.85 | 0 | -7 | 121 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |